Trial · NCT00922883

A Pilot Study of the Thrombopoietin-Receptor Agonist Eltrombopag in Refractory Aplastic Anemia Patients

NCT00922883, Phase 2, Completed, National Heart, Lung, and Blood Institute (NHLBI); results first posted 2018-07-16

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. A Pilot Study of the Thrombopoietin-Receptor Agonist Eltrombopag in Refractory Aplastic Anemia Patients. Trials, record NCT00922883. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00922883

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: A Pilot Study of the Thrombopoietin-Receptor Agonist Eltrombopag in Refractory Aplastic Anemia Patients
NCT number: NCT00922883
Status: Completed
Phases: Phase 2
Enrollment: 43 participants, actual
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Conditions: Anemia, Aplastic, Anemia, Hypoplastic, Thrombocytopenia
Interventions: Eltrombopag
First posted: 2009-06-17
Last updated: 2020-10-20
Results first posted: 2018-07-16

Source ClinicalTrials.gov

Registered outcomes1

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	The Portion of Drug Responders as Defined by Hematologic Improvements	12-16 weeks	Defined as unilineage or multilineage recovery by 1 or more of the following: 1) platelet response (increase to 20 × 103/μL above baseline or stable platelet counts with transfusion independence for a minimum of 8 weeks in those who were transfusion dependent on entry into the protocol); (2) erythroid response (when pretreatment hemoglobin was \<9 g/dL, defined as an increase in hemoglobin by 1.5 g/dL or, in transfused patients, a reduction in the units of packed red blood cell transfusions by an absolute number of at least 4 transfusions for 8 consecutive weeks, compared with the pretreatment transfusion number in the previous 8 weeks); and (3) neutrophil response (when pretreatment absolute neutrophil count \[ANC\] of \<0.5 × 103/μL as at least a 100% increase in ANC, or an ANC increase \>0.5 × 103/μL, and the toxicity profile as measured using Common Terminology Criteria for Adverse Events).

Source ClinicalTrials.gov

Outcomes1

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	The Portion of Drug Responders as Defined by Hematologic Improvements	12-16 weeks	All subjects who received Eltrombopag were analyzed.	Participants	COUNT_OF_PARTICIPANTS

Source ClinicalTrials.gov

Results by group1

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
The Portion of Drug Responders as Defined by Hematologic Improvements	Eltrombopag		17		Participants

Source ClinicalTrials.gov

Participant flow3

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Eltrombopag	43
Overall Study	COMPLETED	Eltrombopag	43
Overall Study	NOT COMPLETED	Eltrombopag	0

Source ClinicalTrials.gov

Adverse events126

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Febrile neutropenia	Blood and lymphatic system disorders	Eltrombopag	3	43
other	Hyperbilirubinaemia	Blood and lymphatic system disorders	Eltrombopag	1	43
other	Jaundice	Blood and lymphatic system disorders	Eltrombopag	1	43
other	Petechiae	Blood and lymphatic system disorders	Eltrombopag	3	43
other	Purpura	Blood and lymphatic system disorders	Eltrombopag	1	43
other	Chest pain	Cardiac disorders	Eltrombopag	2	43
other	Dizziness	Cardiac disorders	Eltrombopag	4	43
other	Dyspnoea	Cardiac disorders	Eltrombopag	1	43
other	Dyspnoea exertional	Cardiac disorders	Eltrombopag	2	43
other	Cataract	Eye disorders	Eltrombopag	1	43

1 to 10 of 126Source ClinicalTrials.gov

See all 126 adverse events

Adverse event totals3

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Eltrombopag	4	43
Total, other adverse events	Eltrombopag	38	43
Total, serious adverse events	Eltrombopag	16	43

Source ClinicalTrials.gov

Papers5

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
8639762	BACKGROUND	PubMed
16778145	BACKGROUND	PubMed
22762314	RESULT	PubMed
24345753	RESULT	PubMed
30992268	DERIVED	PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00922883

GET https://conductscience.org/api/trials/v1/NCT00922883/events?page=2

API reference For AI assistants